"La sopravvivenza a condizioni sfavorevoli richiede una capacità di adattamento che fornisce i migliori risultati quando le modifiche sono massimamente funzionali al nuovo ambiente creatosi.”
La contrazione delle risorse, unitamente a pratiche più rigorose nella valutazione della efficacia dei farmaci ha rappresentato un forte stimolo al cambiamento per l’Industria farmaceutica, che muta le proprie strategie di marketing adattandole alle nuove regole ed alla diversa recettività dei medici “prescrittori”.
Bibliografia
1. Landefeld CS, Steinman MA The Neurontin legacy--marketing through misinformation and manipulation. N Engl J Med. 2009; 360: 103-6.
2. Vedula SS et al Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009; 361:1963-71
3. Choudhry NK et al. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002; 287: 612-17.
4. ESC Task Force Focused update of the ESC Guidelines for the management of atrial fibrillation Eur Heart J (2012) 33, 2719–2747
5. Nelson HD et al. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2010; 153: 99-111.
6. U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med. 2011; 154: 356-64
7. Davidson RA. Sources of funding and outcomes of clinical trials. J Gen Intern Med. 1996; 1: 1550–1558
8. Ross JS et al Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008; 299: 1800-12.
9. McClung MR et al. Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med. 2001; 344: 333-40.
10.Shepherd J et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360: 1623-30.
Data di Redazione 04/2013